Memotril Review and Ads Breakdown: A Research-First Look

What Is Memotril?

Based on the available transcript and its market context, Memotril is a cognitive health supplement targeted at adults who are experiencing, or fear experiencing, the early stages of memory decline. It sits in a crowded and commercially active subcategory of the nutraceuticals market, the "brain health" or "nootropic" segment. Which, according to market research firm Grand View Research, was valued at approximately $3.7 billion globally in 2023 and is projected to grow at a compound annual rate of over 14 percent through the end of the decade. The product format appears to be an oral supplement, though the specific delivery mechanism (capsule, tablet, softgel, liquid) is not specified in the VSL transcript.

The market positioning is squarely in the early-intervention lane: Memotril does not present itself as a treatment for diagnosed dementia but rather as a preventive or protective measure for individuals who have noticed the kind of subtle cognitive slippage. A forgotten appointment, a name that won't come, a reluctance to socialize; that they fear might mean something more serious. This is a strategically intelligent position. It sidesteps FDA regulatory territory around disease treatment claims while still benefiting from the enormous emotional weight that the word "Alzheimer's" carries. The stated target user, extrapolated from the ad's language and symptom framing, is an adult between roughly 45 and 70 years of age who has personal or family experience with cognitive decline and is actively looking for something to do about it.

Importantly, the VSL does not disclose pricing, ingredients, or the full offer in the fragment available. The ad functions as a top-of-funnel awareness and click driver, its job is to get a specific, fear-activated audience to the landing page, where the full pitch, ingredient stack, and purchase mechanism presumably live. Evaluating the product's efficacy therefore requires reasoning from the category norms and from what we know about the science of cognitive support supplementation generally, rather than from Memotril's own disclosed formulation.

The Problem It Targets

Alzheimer's disease and related dementias represent one of the most significant and least-solved public health challenges of the 21st century. The World Health Organization estimates that approximately 55 million people worldwide live with dementia, with nearly 10 million new cases diagnosed each year. In the United States, the Alzheimer's Association projects that by 2050, the number of Americans over 65 living with Alzheimer's will nearly double to approximately 13 million, barring a medical breakthrough. These numbers are not abstract; they translate into tens of millions of family members who have watched a parent, grandparent, or spouse lose themselves to the disease and who carry that experience as a visceral, personal fear about their own trajectory.

The scientific dimension of the VSL's opening claim, that Alzheimer's pathology is detectable in the brain decades before clinical symptoms emerge, is, notably, accurate. Research published in journals including The Lancet Neurology and JAMA Neurology has established that amyloid-beta plaques and tau tangles, the hallmark pathological features of Alzheimer's, can be identified via PET imaging and cerebrospinal fluid biomarkers 15 to 20 years before the onset of measurable cognitive impairment. This finding, which has been central to the field since the early 2010s work of researchers including Reisa Sperling at Harvard and Clifford Jack at the Mayo Clinic, is now widely accepted in the neurological community. The VSL is not inventing this claim, it is appropriating a genuine scientific insight and deploying it in a commercial context.

The commercial opportunity created by this scientific reality is significant. If Alzheimer's begins silently, then every adult who forgets a name, misses an appointment, or notices that social engagement feels more effortful than it once did has grounds to worry, and grounds to buy something that promises protection. The VSL leans heavily into this ambiguity, presenting symptoms that are, in the majority of cases, attributable to ordinary stress, poor sleep, aging-related processing-speed changes, or depression rather than early-stage neurodegeneration. The gap between "these symptoms overlap with early Alzheimer's warning signs" and "you may have early Alzheimer's" is clinically significant, but the ad collapses it, a rhetorical move that is effective precisely because it is not technically false.

What the VSL does not acknowledge is the equally well-established research on modifiable risk factors for dementia. A landmark 2020 report from the Lancet Commission on Dementia Prevention, Intervention, and Care identified twelve modifiable risk factors, including physical inactivity, smoking, hypertension, obesity, and social isolation. That together account for approximately 40 percent of dementia cases worldwide. The supplement industry's framing tends to exclude this context, because the honest answer to "how do I prevent cognitive decline?" is less often "take this capsule" and more often "exercise regularly, sleep adequately, maintain social connections, and manage cardiovascular risk factors." Memotril's pitch operates in the space that context leaves open.

Curious how other VSLs in this niche structure their pitch? Keep reading. The section below breaks down the psychology behind every claim in this ad.

How Memotril Works

The VSL transcript does not disclose a specific mechanism of action for Memotril. What it does instead is borrow the mechanism from the science it invokes: Alzheimer's starts early, symptoms are recognizable if you know what to look for, and intervention; implied to be Memotril, should begin before the window closes. The product's own biological pathway is left to the reader's inference, which is a deliberate and common technique in supplement advertising. By grounding the pitch in real science (the pre-symptomatic phase of Alzheimer's) without explicitly claiming that the product addresses that science, the advertiser avoids specific efficacy claims while allowing the association to form in the viewer's mind.

In the broader cognitive supplement category, the mechanisms most commonly invoked fall into several clusters: neuroprotection via antioxidant action (compounds that reduce oxidative stress in neural tissue), cholinergic support (ingredients that increase acetylcholine availability, the neurotransmitter most directly implicated in memory), cerebral blood flow enhancement, neuroinflammation reduction, and neuroplasticity support via brain-derived neurotrophic factor (BDNF) pathways. Most well-researched cognitive supplements act on one or more of these pathways with varying degrees of clinical evidence behind them, some ingredients, like Bacopa monnieri and Lion's Mane mushroom, have genuine peer-reviewed evidence in human trials; others, like many proprietary blends, have evidence primarily from in-vitro or animal studies.

Without Memotril's disclosed formulation, it is not possible to evaluate whether its specific mechanism of action is plausible, established, or speculative. What can be said with confidence is that the category-level science on cognitive supplementation is genuinely mixed. A 2019 systematic review in The Journal of Nutrition, Health & Aging concluded that while several individual compounds show promise for cognitive support in older adults, the evidence base for most commercially available multi-ingredient nootropic blends remains limited by small sample sizes, short study durations, and industry funding. This does not mean such products cannot work; it means the evidence architecture is not yet strong enough to support confident conclusions in either direction.

The honest position for a consumer researching Memotril is this: the problem the product targets is real, the science invoked in the VSL is largely accurate in its outlines, and the general category of cognitive support supplementation has plausible biological rationale behind it. Whether Memotril's specific formulation delivers on that rationale is a question the available transcript cannot answer, and one that the product's own marketing, as observed here, is careful not to fully raise.

Key Ingredients and Components

Because the VSL transcript does not disclose Memotril's formulation, the following section draws on the ingredients most commonly found in cognitive health supplements that are marketed using an early-intervention, Alzheimer's-prevention framing. If Memotril's full ingredient panel becomes available, each of these should be verified against the actual label.

• Bacopa Monnieri: An Ayurvedic herb with the most extensive clinical evidence base of any nootropic ingredient. Multiple randomized controlled trials, including a 2012 study by Pase and colleagues published in the Journal of Psychopharmacology, have found that chronic supplementation (12+ weeks) improves measures of memory acquisition and retention in healthy older adults. The mechanism is thought to involve enhanced synaptic communication and reduced cholinesterase activity.

• Lion's Mane Mushroom (Hericium erinaceus): A functional mushroom that has attracted significant attention for its ability to stimulate nerve growth factor (NGF) synthesis, a protein critical to the maintenance and regeneration of neurons. A 2009 double-blind placebo-controlled trial by Mori and colleagues in Phytotherapy Research found improvements in mild cognitive impairment among older Japanese adults who consumed Lion's Mane for 16 weeks. Evidence remains preliminary but is biologically plausible.

• Phosphatidylserine: A phospholipid naturally present in neural cell membranes. The FDA has granted it a qualified health claim for cognitive dysfunction, though with the caveat that the evidence is limited. Several trials have shown modest improvements in memory and executive function in older adults with age-associated memory impairment, making it one of the better-supported ingredients in the category.

• Ginkgo Biloba: One of the most studied and most contentious nootropic ingredients. While widely used and historically associated with cerebral blood flow improvement, the large-scale Ginkgo Evaluation of Memory (GEM) study, funded by the National Institutes of Health, found that Ginkgo biloba did not reduce the incidence of dementia or Alzheimer's disease in older adults. Smaller studies show mixed results on cognitive performance measures.

• Vitamin B Complex (particularly B6, B9/Folate, B12): B vitamins are involved in homocysteine metabolism, and elevated homocysteine is an established risk factor for cardiovascular disease and has been associated with accelerated cognitive decline. Supplementation reduces homocysteine levels, and a trial by Smith and colleagues at the University of Oxford (PLOS ONE, 2010) found that B-vitamin supplementation slowed brain atrophy in regions specifically affected by Alzheimer's pathology in individuals with mild cognitive impairment.

• Alpha-GPC: A choline compound that crosses the blood-brain barrier and serves as a precursor to acetylcholine. Used clinically in Europe as a treatment for Alzheimer's symptoms, Alpha-GPC has a stronger clinical evidence base than most over-the-counter nootropics, with several Italian multicenter trials showing cognitive improvements in patients with mild-to-moderate Alzheimer's.

Hooks and Ad Angles

The opening line of the Memotril ad, "So what are the earliest signs of Alzheimer's?", is a near-perfect example of what Eugene Schwartz would have recognized as a Stage 4 or Stage 5 market sophistication move. By 2024, the supplement-buying audience for cognitive health products has seen thousands of iterations of the standard pitch: "boost your memory," "sharpen your focus," "fight brain fog." Those direct benefit claims have been so thoroughly saturated that they register as ambient noise for the sophisticated, high-intent buyer. The question-based hook sidesteps the pitch entirely and enters through the back door of information, it presents itself not as advertising but as a public-health announcement, borrowing the register of a doctor's patient education video rather than a product commercial. This is a pattern interrupt in the technical sense: it disrupts the viewer's habituated scroll response by presenting a stimulus that doesn't match the expected category.

What follows the opening question deepens the hook through a technique that direct-response practitioners call symptom mirroring, the rapid enumeration of recognizable, everyday behaviors (missing appointments, withdrawing from social gatherings) reframed as potential medical symptoms. The psychological mechanism here is Festinger's cognitive dissonance: the viewer recognizes their own behavior in the list, the ad assigns that behavior alarming clinical significance, and the resulting discomfort can only be resolved by taking the action the ad offers. Crucially, the symptoms named are universal enough that nearly any viewer over 45 will have experienced at least one of them in the past month. The hook is not targeted at people who have Alzheimer's; it is targeted at people who fear they might.

Secondary hooks observed in the VSL:

• "We actually see it in the brain decades before we have any symptoms". Authority-building claim that primes urgency
• "You may experience problems with dates and times, calendars, missing appointments". Symptom mirror designed to generate self-identification
• "People typically start withdrawing from social activities"; social consequence framing that adds emotional weight beyond the cognitive fear
• "That's why you shouldn't ignore the early warning signs", implicit accusation framing; positions inaction as negligence

Ad headline variations for Meta or YouTube testing:

• "Doctors Say Alzheimer's Starts 20 Years Before Symptoms, Here's What to Watch For"
• "Forgetting Things More Often? This Could Be Why (And What to Do About It)"
• "The 4 Early Warning Signs of Cognitive Decline Most People Dismiss as Normal Aging"
• "Are You Missing These Early Alzheimer's Signals? Watch Before It's Too Late"
• "Why Withdrawing from Social Life Is One of the First Signs Neurologists Look For"

Psychological Triggers and Persuasion Tactics

The persuasive architecture of this VSL is compact but structurally sophisticated. In fewer than 100 words, it stacks three of Cialdini's six influence principles, authority, social proof (inverted, via social withdrawal as a symptom), and scarcity, alongside Kahneman and Tversky's loss aversion and Loewenstein's curiosity gap. What is particularly notable is that these triggers are not deployed in parallel (multiple independent appeals happening simultaneously) but in a stacked sequential structure: each element builds on the credibility and emotional temperature established by the element before it. The clinical voice establishes authority first, creating the conditions under which the symptom list will be taken seriously; the symptom list activates loss aversion; and the closing urgency phrase converts that activated fear into a specific action. The sequence is disciplined.

This is the structure that the best direct-response copywriters, including Gary Bencivenga, Clayton Makepeace, and the Agora Financial stable of writers, have used for decades in health supplement advertising, because it mirrors the psychological journey of a person who has just received bad news from a doctor: disorienting information, personal relevance recognition, and an urgent need to act. The VSL compresses that journey into thirty seconds.

• Fear appeal and loss aversion (Kahneman & Tversky, Prospect Theory, 1979): The entire narrative is structured around potential loss, of memory, of independence, of self. Rather than around potential gain. The brain weighs losses approximately twice as heavily as equivalent gains, and this ad is built entirely on that asymmetry.

• Pattern interrupt via clinical questioning (Cialdini, Pre-Suasion, 2016): The opening question hijacks the viewer's attention by mimicking the form of a public-health video rather than an advertisement, lowering the viewer's persuasion defenses before the pitch begins.

• Symptom identification and self-diagnosis trigger (Festinger, cognitive dissonance theory, 1957): The enumeration of common behaviors reframed as symptoms creates internal conflict in any viewer who recognizes themselves, a tension the CTA offers to resolve.

• Borrowed authority via white-coat framing (Cialdini, authority principle; Milgram's obedience studies, 1963): The use of first-person plural clinical language ("we actually see it") implies a medical speaker without naming one, exploiting the heuristic that clinical-sounding language signals expertise.

• Open loop / curiosity gap (Loewenstein, information gap theory, 1994): The hook raises a question the ad does not answer, driving the viewer to click in order to close the informational gap. One of the most reliable mechanisms in digital advertising.

• Temporal scarcity / urgency framing (Thaler, endowment effect; FOMO-based urgency): "Before it's too late" functions as a closing scarcity device; not product scarcity (limited stock) but temporal scarcity (a closing biological window), which is a harder claim to verify and therefore a harder urgency to dismiss.

• Implicit accusation frame (rhetorical device in direct response; related to Cialdini's commitment and consistency): The phrase "you shouldn't ignore the early warning signs" subtly reframes inaction not as a neutral choice but as an act of negligence, leveraging the viewer's self-image as a responsible adult to motivate the click.

Want to see how these tactics compare across 50+ VSLs in the health supplement niche? That's exactly what Intel Services is built to show you.

Scientific and Authority Signals

The authority architecture of the Memotril VSL is interesting precisely because of what it does not do. It names no expert. It cites no study by title or author. It names no institution. Instead, it relies on what might be called ambient authority, the use of clinical register, first-person plural medical framing, and a scientifically accurate claim (the pre-symptomatic timeline of Alzheimer's pathology) to create the impression of institutional backing without actually providing any. The voice says "we actually see it in the brain decades before we have any symptoms," and the "we" does enormous work: it implies a community of researchers or clinicians, it positions the speaker as a member of that community, and it grounds the claim in what sounds like observational clinical experience. None of that is established by the transcript.

The underlying factual claim, however, is legitimate. The science of Alzheimer's biomarker research has consistently found that amyloid pathology precedes clinical symptoms by 15-20 years or more. This has been documented in longitudinal studies including the work of the Dominantly Inherited Alzheimer Network (DIAN) study group, published in The New England Journal of Medicine, and in observational cohort work from the Mayo Clinic Study of Aging. The VSL is not fabricating science, it is selectively deploying accurate science in a context that implies the product can address it, without making that causal claim explicitly.

This is a form of what might be called borrowed authority rather than genuine authority: the claim belongs to the scientific literature, not to the product, but the juxtaposition of accurate science and a product CTA allows the audience to draw an inference the advertiser does not technically make. It is a sophisticated strategy precisely because it is difficult to challenge, the science is real, the product's relationship to that science is simply never stated. From a consumer protection standpoint, the gap between "Alzheimer's starts early" and "Memotril helps prevent that early start" is not bridged by evidence in this VSL; from a marketing standpoint, the gap is bridged by implication, and implication is the most durable form of advertising claim.

For a consumer evaluating this product, the relevant question is not whether the science cited is accurate (it is, broadly) but whether there is peer-reviewed clinical evidence that Memotril's specific formulation, at its specific doses, produces meaningful cognitive benefit in the target population. That question cannot be answered from the transcript provided, and in its absence, the authority signals in the ad should be read as rhetorical rather than evidentiary.

The Offer, Pricing, and Risk Reversal

The transcript available does not disclose price, bonuses, guarantee structure, or any other offer components, a feature consistent with its function as a top-of-funnel ad rather than a full-length VSL. The ad's sole conversion mechanism is the click: "Click learn more and find out how to prevent cognitive decline before it's too late." Everything about the offer, pricing, bundling, money-back guarantee, and any value-stacking, is withheld and presumably housed on the destination landing page or a longer video sales letter that the click reveals.

This two-stage funnel structure is standard practice in the supplement industry and serves multiple functions. It allows the advertiser to pre-qualify clicks by emotional activation (only viewers who are genuinely worried about cognitive decline will click an Alzheimer's warning sign ad), ensuring that traffic arriving at the offer page is already primed and partially committed. It also means the ad itself can remain free of price claims and specific health claims that might trigger platform ad-review systems on Meta or YouTube, claims that are better made in the owned environment of a landing page where FTC compliance decisions are more directly in the seller's control. The urgency framing ("before it's too late") is the only offer mechanic visible in the available transcript, and it functions as temporal pressure rather than conventional scarcity.

Who This Is For (and Who It Isn't)

The ideal buyer for Memotril, as constructed by this VSL, is a specific and identifiable person. They are most likely between 45 and 70 years old. They have noticed, in the past year or two, that their memory feels less reliable than it once did. Names take longer to surface, they occasionally walk into a room and forget why, and keeping track of appointments requires more effort than it used to. Critically, they have a family member who experienced dementia or Alzheimer's, which means their fear is not abstract but experiential and emotionally charged. They are health-conscious and willing to spend money on supplements. They likely already take a multivitamin and may take fish oil or vitamin D. They respond to clinical framing and find science-adjacent language reassuring. This is a large demographic; the combination of aging Baby Boomers and health-aware Gen X adults makes it one of the most commercially valuable segments in consumer health.

For this person, a well-formulated cognitive support supplement with genuine clinical evidence behind its ingredients may represent a reasonable, low-risk addition to a broader brain health strategy; provided they understand that supplementation is additive to, not a replacement for, the lifestyle factors (exercise, sleep, social engagement, cardiovascular health management) that the peer-reviewed literature identifies as the primary levers of cognitive longevity. If that framing resonates, and if Memotril's undisclosed formulation turns out to include evidence-backed ingredients at clinically relevant doses, then the product merits genuine consideration.

The readers who should approach with more caution are those who are experiencing significant, progressive, or functionally impairing cognitive changes, the kind that affect their ability to work, manage finances, or navigate familiar environments. For this group, a supplement advertisement is not the appropriate first stop; a neurologist or geriatrician is. The VSL's framing, which presents the product as an early-intervention tool, could plausibly delay necessary clinical evaluation for someone whose symptoms warrant it. That is a meaningful risk, and it is worth naming plainly.

If you are researching this product as part of a broader evaluation of the cognitive supplement market, the Intel Services library includes analyses of comparable VSLs and can help you identify patterns across the category.

Frequently Asked Questions

Q: What is Memotril and what does it claim to do?
A: Memotril is a cognitive health supplement marketed as a tool for preventing or slowing cognitive decline, particularly in adults who are experiencing early warning signs associated with Alzheimer's disease. Its marketing focuses on the science of pre-symptomatic Alzheimer's pathology, the finding that brain changes begin decades before clinical symptoms appear, to position early supplementation as a protective measure. The specific ingredients and mechanism of action are not disclosed in the available VSL transcript.

Q: Is Memotril a scam?
A: Based on the available marketing material, there is no evidence to characterize Memotril as an outright scam. The scientific claims made in its advertising are largely accurate in outline. However, the VSL does not disclose ingredients, clinical evidence for the specific formulation, or third-party testing data, the absence of which makes independent evaluation difficult. Consumers should look for a full ingredient panel, dose disclosures, and any clinical studies the manufacturer cites before purchasing.

Q: Does Memotril really work for memory loss?
A: The available transcript does not disclose the formulation, so it is not possible to evaluate efficacy directly. Whether any supplement "works" for memory loss depends heavily on which specific ingredients are included, at what doses, and in which population. Some cognitive supplement ingredients, including Bacopa monnieri, phosphatidylserine, and Lion's Mane mushroom, have legitimate peer-reviewed evidence supporting modest cognitive benefits in older adults. Others have weaker or mixed evidence.

Q: What are the side effects of Memotril?
A: Without a disclosed ingredient list, specific side effect assessment is not possible. Most cognitive supplements are generally well tolerated, but individual ingredients can carry considerations: Bacopa monnieri can cause gastrointestinal discomfort in some users; Ginkgo biloba has a mild blood-thinning effect and may interact with anticoagulants; high-dose B vitamins are generally safe but can interact with certain medications. Anyone on prescription medications or with existing health conditions should consult a physician before starting any new supplement.

Q: Is Memotril safe to take?
A: Again, without a full ingredient and dosage disclosure, a definitive safety assessment is not possible here. As a general principle, dietary supplements are not subject to the same pre-market clinical testing requirements as pharmaceutical drugs in the United States. Look for products that are manufactured in FDA-registered facilities, carry a cGMP (Current Good Manufacturing Practices) certification, and have been third-party tested for purity and potency.

Q: Can a supplement actually prevent Alzheimer's disease?
A: No supplement has been approved by the FDA or any equivalent regulatory authority to prevent, treat, or cure Alzheimer's disease. Some individual ingredients have shown promise in reducing risk factors or supporting cognitive function in specific populations, but the evidence for primary prevention of Alzheimer's through supplementation remains preliminary. The most robust evidence for dementia risk reduction involves lifestyle factors: regular aerobic exercise, adequate sleep, social engagement, and management of cardiovascular risk factors.

Q: Who should take Memotril?
A: Based on the VSL's framing, the product appears designed for adults between roughly 45 and 70 who are experiencing mild, age-related cognitive changes and want to take a proactive approach to brain health. It is not appropriate as a substitute for clinical evaluation for anyone experiencing significant, progressive, or functionally impairing cognitive symptoms. Those with existing medical conditions, those on prescription medications, and pregnant or breastfeeding individuals should consult a qualified healthcare provider before use.

Q: Where can I find Memotril's full ingredient list?
A: The ingredient panel was not disclosed in the VSL transcript analyzed here. Consumers should look for this information on the product's official website, ideally in a Supplement Facts panel that lists each ingredient and its dose per serving. If that information is not readily available on the product page, that absence is itself a signal worth noting.

Final Take

The Memotril VSL, in the form available for analysis, is a technically competent piece of fear-based direct-response advertising built on a foundation of genuine scientific concern. Its creators understand their audience's psychology with precision: they know that the fear of Alzheimer's is not abstract, that it is held most intensely by people who have watched a family member lose themselves to the disease, and that this fear is most easily activated not through statistics but through symptom recognition, the moment a viewer hears "missing appointments" or "withdrawing from social activities" and realizes they have been doing exactly that. The ad does not need to be long because the emotional infrastructure it exploits is already built. It only needs to strike the right nerve, and it does.

The weaknesses of the VSL are equally instructive. The complete absence of ingredient disclosure, mechanism specificity, clinical evidence, named experts, or any form of verifiable authority claim means that the product's actual value proposition is entirely opaque in this ad. That opacity may be a deliberate strategic choice. Reserving the full pitch for the landing page where engaged, pre-qualified buyers are more likely to convert. But it also means that a skeptical viewer has nothing to evaluate except the feeling the ad generates. In a category where consumer trust has been repeatedly damaged by products that promise what the science cannot support, the decision to lead entirely with fear rather than even a fragment of substance is a risk worth noting.

For the market researcher or media buyer, the key insight this VSL offers is about audience sophistication and ad-fatigue management. The supplement buyer who fears cognitive decline in 2024 has seen the "boost your brain" pitch in every conceivable form. The Memotril approach; entering through a question that sounds like public health information, grounding the pitch in real science, and converting on urgency rather than features, is a meaningful evolution of the category's creative approach. Whether it is sustainable depends on whether the product behind the pitch is strong enough to generate the repeat purchases and word-of-mouth that keep a supplement brand viable after the initial acquisition.

The honest summary for a consumer researching Memotril before buying: the fear this ad activates is legitimate, the science it cites is broadly accurate, and the category of cognitive support supplementation has enough biological plausibility to warrant serious consideration. But the specific product requires far more transparency than this VSL provides before it earns the trust of a well-informed buyer. Look for the full ingredient panel, look for dose disclosures, look for any independent testing, and treat the urgency framing as a rhetorical device rather than a medical opinion.

This breakdown is part of Intel Services, our ongoing library of VSL and ad-copy analyses across the health, finance, and wellness categories. If you are researching similar products, keep reading.

Disclaimer: This article is for research and educational purposes only. It is not medical, legal, or financial advice, and it is not affiliated with the product or its makers. Always consult a qualified professional before making health or financial decisions.